Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CERC NASDAQ:GLTO NASDAQ:HOOK NASDAQ:ORMP NASDAQ:OVID On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCERCCerecor$11.83-0.4%$2.60$1.98▼$4.50$1.14B1.441.27 million shs323,673 shsGLTOGalecto$2.87$3.29$2.01▼$14.12$3.80M1.35253,576 shs34,794 shsHOOKHOOKIPA Pharma$0.92+2.6%$0.93$0.72▼$4.74$11.26M0.97113,428 shs11,704 shsORMPOramed Pharmaceuticals$2.34-4.1%$2.18$1.82▼$3.09$100.05M1.6990,135 shs252,657 shsOVIDOvid Therapeutics$1.21-0.8%$0.88$0.24▼$1.47$86.75M0.351.49 million shs997,399 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCERCCerecor+4.85%+9.19%+33.56%+156.03%+26.14%GLTOGalecto0.00%0.00%-14.96%-13.45%-79.10%HOOKHOOKIPA Pharma+2.62%-0.47%+13.03%-28.37%-80.00%ORMPOramed Pharmaceuticals-4.10%-2.90%+13.04%+9.86%-3.31%OVIDOvid Therapeutics-0.82%-3.97%+27.37%+289.82%+14.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCERCCerecor$11.83-0.4%$2.60$1.98▼$4.50$1.14B1.441.27 million shs323,673 shsGLTOGalecto$2.87$3.29$2.01▼$14.12$3.80M1.35253,576 shs34,794 shsHOOKHOOKIPA Pharma$0.92+2.6%$0.93$0.72▼$4.74$11.26M0.97113,428 shs11,704 shsORMPOramed Pharmaceuticals$2.34-4.1%$2.18$1.82▼$3.09$100.05M1.6990,135 shs252,657 shsOVIDOvid Therapeutics$1.21-0.8%$0.88$0.24▼$1.47$86.75M0.351.49 million shs997,399 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCERCCerecor+4.85%+9.19%+33.56%+156.03%+26.14%GLTOGalecto0.00%0.00%-14.96%-13.45%-79.10%HOOKHOOKIPA Pharma+2.62%-0.47%+13.03%-28.37%-80.00%ORMPOramed Pharmaceuticals-4.10%-2.90%+13.04%+9.86%-3.31%OVIDOvid Therapeutics-0.82%-3.97%+27.37%+289.82%+14.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCERCCerecor 0.00N/AN/AN/AGLTOGalecto 3.00Buy$10.00248.43% UpsideHOOKHOOKIPA Pharma 2.33Hold$4.50387.01% UpsideORMPOramed Pharmaceuticals 0.00N/AN/AN/AOVIDOvid Therapeutics 3.17Buy$3.10156.20% UpsideCurrent Analyst Ratings BreakdownLatest ORMP, CERC, OVID, GLTO, and HOOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025OVIDOvid TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.00(Data available from 9/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCERCCerecor$6.70M169.52N/AN/A$0.22 per share53.77GLTOGalectoN/AN/AN/AN/A$10.99 per shareN/AHOOKHOOKIPA Pharma$9.35M1.20N/AN/A$4.25 per share0.22ORMPOramed Pharmaceuticals$1.34M71.60N/AN/A$3.61 per share0.65OVIDOvid Therapeutics$570K150.95N/AN/A$0.96 per share1.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCERCCerecor-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/AGLTOGalecto-$21.44M-$13.13N/AN/AN/AN/A-115.70%-95.42%11/7/2025 (Estimated)HOOKHOOKIPA Pharma-$43.50M-$5.85N/AN/AN/A-785.66%-120.09%-77.14%11/12/2025 (Estimated)ORMPOramed Pharmaceuticals-$19.06M-$0.35N/AN/AN/AN/A-19.37%-18.28%11/6/2025 (Estimated)OVIDOvid Therapeutics-$26.43M-$0.53N/AN/AN/A-574.44%-58.87%-43.18%11/11/2025 (Estimated)Latest ORMP, CERC, OVID, GLTO, and HOOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ORMPOramed Pharmaceuticals-$0.04-$0.05-$0.01$0.31N/AN/A8/13/2025Q2 2025OVIDOvid Therapeutics-$0.16-$0.06+$0.10-$0.06$0.09 million$6.27 million8/5/2025Q2 2025GLTOGalectoN/A-$2.60N/A-$2.60N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCERCCerecorN/AN/AN/AN/AN/AGLTOGalectoN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCERCCerecor0.792.192.18GLTOGalectoN/A4.964.96HOOKHOOKIPA PharmaN/A3.613.61ORMPOramed PharmaceuticalsN/A26.8226.81OVIDOvid Therapeutics0.234.724.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCERCCerecor62.84%GLTOGalecto14.20%HOOKHOOKIPA Pharma63.88%ORMPOramed Pharmaceuticals12.73%OVIDOvid Therapeutics72.24%Insider OwnershipCompanyInsider OwnershipCERCCerecor45.70%GLTOGalecto10.80%HOOKHOOKIPA Pharma3.30%ORMPOramed Pharmaceuticals17.80%OVIDOvid Therapeutics13.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCERCCerecor3196.01 millionN/ANot OptionableGLTOGalecto401.32 million1.18 millionOptionableHOOKHOOKIPA Pharma16012.19 million11.79 millionOptionableORMPOramed Pharmaceuticals1041.00 million33.71 millionOptionableOVIDOvid Therapeutics6071.11 million61.80 millionOptionableORMP, CERC, OVID, GLTO, and HOOK HeadlinesRecent News About These CompaniesOvid Therapeutics Regains Nasdaq ComplianceSeptember 16, 2025 | msn.comOvid Therapeutics (NASDAQ:OVID) Receives $3.10 Average Price Target from AnalystsSeptember 10, 2025 | americanbankingnews.comOvid Therapeutics (NASDAQ:OVID) Receives Average Recommendation of "Buy" from BrokeragesSeptember 8, 2025 | marketbeat.comHC Wainwright Cuts Earnings Estimates for Ovid TherapeuticsAugust 29, 2025 | marketbeat.comAffinity Asset Advisors LLC Invests $208,000 in Ovid Therapeutics $OVIDAugust 28, 2025 | marketbeat.comLucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 TargetAugust 24, 2025 | finance.yahoo.comLucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 TargetAugust 23, 2025 | insidermonkey.comOvid Therapeutics (NASDAQ:OVID) Short Interest Up 54.8% in JulyAugust 22, 2025 | marketbeat.comSpotlight On 3 Promising Penny Stocks With Over $60M Market CapAugust 20, 2025 | uk.finance.yahoo.comOvid Therapeutics Second Quarter 2025 Earnings: Beats ExpectationsAugust 16, 2025 | finance.yahoo.comOvid Therapeutics Reports Increased Revenue Amid ChallengesAugust 14, 2025 | msn.comOvid Therapeutics Navigates FDA Disruptions and Government ChallengesAugust 14, 2025 | tipranks.comOvid Therapeutics: Strategic Advances and Promising Developments Justify Buy RatingAugust 13, 2025 | tipranks.comOvid Therapeutics initiated with a Buy at Lucid CapitalAugust 13, 2025 | msn.comOvid Therapeutics Transfers Stock to Nasdaq Capital MarketAugust 13, 2025 | msn.comOvid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue EstimatesAugust 13, 2025 | zacks.comOvid Therapeutics Reports Business Updates and Second Quarter 2025 Financial ResultsAugust 13, 2025 | globenewswire.comLucid Capital Markets initiates Ovid Therapeutics stock with Buy ratingAugust 13, 2025 | investing.comAmit Rakhit: Global Access, Local Wisdom — How Biotech Thrives Amid Regulatory ComplexityAugust 13, 2025 | msn.comB.Riley assumes coverage on Ovid Therapeutics stock with Buy ratingAugust 8, 2025 | investing.comOvid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica PharmaJuly 25, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSmall Cap, Big Potential: 3 Tech Disruptors You Should Know AboutBy Nathan Reiff | August 22, 2025Is It Too Late to Jump on the Nuclear Bandwagon? By Jordan Chussler | August 25, 2025What August Labor Data Means for the S&P 500 in SeptemberBy Thomas Hughes | September 8, 2025AI Exposure Without the Hype: 3 ETFs That Offer Smarter AI BetsBy Nathan Reiff | August 25, 2025As the Market Rotates, This Healthcare ETF Is Leading the WayBy Jordan Chussler | August 26, 2025ORMP, CERC, OVID, GLTO, and HOOK Company DescriptionsCerecor NASDAQ:CERCCerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.Galecto NASDAQ:GLTO$2.87 0.00 (0.00%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$2.87 0.00 (0.00%) As of 09/19/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.HOOKIPA Pharma NASDAQ:HOOK$0.92 +0.02 (+2.62%) As of 09/19/2025 03:57 PM EasternHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Oramed Pharmaceuticals NASDAQ:ORMP$2.34 -0.10 (-4.10%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$2.38 +0.04 (+1.71%) As of 09/19/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.Ovid Therapeutics NASDAQ:OVID$1.21 -0.01 (-0.82%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$1.22 +0.01 (+0.41%) As of 09/19/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Azure Leads While AI Excitement Fuels Microsoft Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
